' 
![]()
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8
USERS' SCORE
Good
Based on 1 Review
8.6
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin D3 (as Cholecalciferol) (from Lanolin)
125 mcg (5,000 IU)
625%
Top Medical Research Studies
8
Vitamins D3 and B2 inhibit gout
The inhibitory kinetics and mechanism of dietary vitamins D3 and B2 on xanthine oxidase.
Direct relation to gout treatment
We investigated how dietary vitamins D3 and B2 can influence gout by inhibiting an enzyme called xanthine oxidase (XO), which plays a significant role in gout development. Through various analytical techniques, we found that vitamin D3 works by fitting into the active site of XO, effectively blocking it from interacting with its substrate, xanthine. This action is due to D3’s ability to form bonds with the enzyme, which leads to a more compact structure that restrains xanthine binding.
On the other hand, vitamin B2 showed a mixed-type inhibition. It binds near the active site, impacting the enzyme's flexibility and structure. This alteration can fold over sections that block substrate access, thereby reducing the enzyme's activity. Remarkably, we noted a synergistic effect when both vitamins were present, heightening their ability to inhibit XO within specific concentration ranges.
Our findings shed light on how vitamins D3 and B2 could be valuable in the dietary management of gout, especially regarding their potential roles as supplementary treatments. Overall, we believe these insights might encourage further exploration into the use of vitamins in supporting gout therapies.
On the other hand, vitamin B2 showed a mixed-type inhibition. It binds near the active site, impacting the enzyme's flexibility and structure. This alteration can fold over sections that block substrate access, thereby reducing the enzyme's activity. Remarkably, we noted a synergistic effect when both vitamins were present, heightening their ability to inhibit XO within specific concentration ranges.
Our findings shed light on how vitamins D3 and B2 could be valuable in the dietary management of gout, especially regarding their potential roles as supplementary treatments. Overall, we believe these insights might encourage further exploration into the use of vitamins in supporting gout therapies.
Read More
8
Vitamin D3 levels not beneficial
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
Relationship between vitamin D3 and gout
We assessed the relationship between vitamin D3 levels and gout by examining 114 male patients with primary gout and 51 healthy male controls. Our findings revealed that patients with gout had significantly lower serum levels of 1,25(OH)2-vitamin D3 compared to the control group. In fact, the concentrations were 38.4 pg/mL for gout patients versus 44.4 pg/mL for the controls.
Interestingly, we did not observe any notable differences in the levels of 25(OH)-vitamin D3 or parathyroid hormone (PTH) between the two groups, indicating that the lower levels of vitamin D3 specifically pertained to the active form relevant to calcium metabolism and bone health. Moreover, we found that uric acid levels were considerably higher in gout patients and that there was a significant negative correlation between uric acid and vitamin D3 levels.
After treating patients with uric acid-lowering medications such as allopurinol or benzbromarone for a year, we noted a significant increase in serum levels of 1,25(OH)2-vitamin D3, while the concentrations of 25(OH)-vitamin D3 and PTH remained unchanged. This suggests that high levels of uric acid may inhibit the activity of the enzyme responsible for converting vitamin D to its active form, rather than indicating that vitamin D directly impacts gout symptoms.
Overall, while we found a clear relationship showcasing lower vitamin D3 levels associated with gout, the study does not suggest that vitamin D3 treatment directly benefits gout management. Consequently, it seems that addressing uric acid levels may be the more pressing treatment approach in gout management.
Interestingly, we did not observe any notable differences in the levels of 25(OH)-vitamin D3 or parathyroid hormone (PTH) between the two groups, indicating that the lower levels of vitamin D3 specifically pertained to the active form relevant to calcium metabolism and bone health. Moreover, we found that uric acid levels were considerably higher in gout patients and that there was a significant negative correlation between uric acid and vitamin D3 levels.
After treating patients with uric acid-lowering medications such as allopurinol or benzbromarone for a year, we noted a significant increase in serum levels of 1,25(OH)2-vitamin D3, while the concentrations of 25(OH)-vitamin D3 and PTH remained unchanged. This suggests that high levels of uric acid may inhibit the activity of the enzyme responsible for converting vitamin D to its active form, rather than indicating that vitamin D directly impacts gout symptoms.
Overall, while we found a clear relationship showcasing lower vitamin D3 levels associated with gout, the study does not suggest that vitamin D3 treatment directly benefits gout management. Consequently, it seems that addressing uric acid levels may be the more pressing treatment approach in gout management.
Read More
Most Useful Reviews
9.5
Effectively manages gout
I have been taking these vitamin D3 capsules for decades. They help greatly with my gout and seasonal affective disorder, especially in winter when sunlight is scarce. The dosage is ideal, and there's no aftertaste later in the day. The quality ingredients have significantly addressed my D deficiency.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8
8
Vitamins D3 and B2 inhibit gout
The inhibitory kinetics and mechanism of dietary vitamins D3 and B2 on xanthine oxidase.
Direct relation to gout treatment
We investigated how dietary vitamins D3 and B2 can influence gout by inhibiting an enzyme called xanthine oxidase (XO), which plays a significant role in gout development. Through various analytical techniques, we found that vitamin D3 works by fitting into the active site of XO, effectively blocking it from interacting with its substrate, xanthine. This action is due to D3’s ability to form bonds with the enzyme, which leads to a more compact structure that restrains xanthine binding.
On the other hand, vitamin B2 showed a mixed-type inhibition. It binds near the active site, impacting the enzyme's flexibility and structure. This alteration can fold over sections that block substrate access, thereby reducing the enzyme's activity. Remarkably, we noted a synergistic effect when both vitamins were present, heightening their ability to inhibit XO within specific concentration ranges.
Our findings shed light on how vitamins D3 and B2 could be valuable in the dietary management of gout, especially regarding their potential roles as supplementary treatments. Overall, we believe these insights might encourage further exploration into the use of vitamins in supporting gout therapies.
On the other hand, vitamin B2 showed a mixed-type inhibition. It binds near the active site, impacting the enzyme's flexibility and structure. This alteration can fold over sections that block substrate access, thereby reducing the enzyme's activity. Remarkably, we noted a synergistic effect when both vitamins were present, heightening their ability to inhibit XO within specific concentration ranges.
Our findings shed light on how vitamins D3 and B2 could be valuable in the dietary management of gout, especially regarding their potential roles as supplementary treatments. Overall, we believe these insights might encourage further exploration into the use of vitamins in supporting gout therapies.
Read More
8
Vitamin D3 levels not beneficial
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
Relationship between vitamin D3 and gout
We assessed the relationship between vitamin D3 levels and gout by examining 114 male patients with primary gout and 51 healthy male controls. Our findings revealed that patients with gout had significantly lower serum levels of 1,25(OH)2-vitamin D3 compared to the control group. In fact, the concentrations were 38.4 pg/mL for gout patients versus 44.4 pg/mL for the controls.
Interestingly, we did not observe any notable differences in the levels of 25(OH)-vitamin D3 or parathyroid hormone (PTH) between the two groups, indicating that the lower levels of vitamin D3 specifically pertained to the active form relevant to calcium metabolism and bone health. Moreover, we found that uric acid levels were considerably higher in gout patients and that there was a significant negative correlation between uric acid and vitamin D3 levels.
After treating patients with uric acid-lowering medications such as allopurinol or benzbromarone for a year, we noted a significant increase in serum levels of 1,25(OH)2-vitamin D3, while the concentrations of 25(OH)-vitamin D3 and PTH remained unchanged. This suggests that high levels of uric acid may inhibit the activity of the enzyme responsible for converting vitamin D to its active form, rather than indicating that vitamin D directly impacts gout symptoms.
Overall, while we found a clear relationship showcasing lower vitamin D3 levels associated with gout, the study does not suggest that vitamin D3 treatment directly benefits gout management. Consequently, it seems that addressing uric acid levels may be the more pressing treatment approach in gout management.
Interestingly, we did not observe any notable differences in the levels of 25(OH)-vitamin D3 or parathyroid hormone (PTH) between the two groups, indicating that the lower levels of vitamin D3 specifically pertained to the active form relevant to calcium metabolism and bone health. Moreover, we found that uric acid levels were considerably higher in gout patients and that there was a significant negative correlation between uric acid and vitamin D3 levels.
After treating patients with uric acid-lowering medications such as allopurinol or benzbromarone for a year, we noted a significant increase in serum levels of 1,25(OH)2-vitamin D3, while the concentrations of 25(OH)-vitamin D3 and PTH remained unchanged. This suggests that high levels of uric acid may inhibit the activity of the enzyme responsible for converting vitamin D to its active form, rather than indicating that vitamin D directly impacts gout symptoms.
Overall, while we found a clear relationship showcasing lower vitamin D3 levels associated with gout, the study does not suggest that vitamin D3 treatment directly benefits gout management. Consequently, it seems that addressing uric acid levels may be the more pressing treatment approach in gout management.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.6
9.5
Effectively manages gout
I have been taking these vitamin D3 capsules for decades. They help greatly with my gout and seasonal affective disorder, especially in winter when sunlight is scarce. The dosage is ideal, and there's no aftertaste later in the day. The quality ingredients have significantly addressed my D deficiency.
Read More
